Exakte Wirkstoffkennungen und zitierbare Passagen zu Wechselwirkungen, Gegenanzeigen und Nebenwirkungen.
Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
Data from study JP16003, a single-arm study of Herceptin (4 mg/kg IV loading dose and 2 mg/kg IV
weekly) and docetaxel (60 mg/m2 IV) in Japanese women with HER2- positive MBC, suggested that
concomitant administration of Herceptin had no effect on the single dose pharmacokinetics of
docetaxel. Study JP19959 was a substudy of BO18255 (ToGA) performed in male and female
Japanese patients with advanced gastric cancer to study the pharmacokinetics of capecitabine and
cisplatin when used with or without Herceptin. The results of this substudy suggested that the
exposure to the bioactive metabolites (e.g. 5-FU) of capecitabine was not affected by concurrent use of
cisplatin or by concurrent use of cisplatin plus Herceptin. However, capecitabine itself showed higher
concentrations and a longer half-life when combined with Herceptin. The data also suggested that the
pharmacokinetics of cisplatin were not affected by concurrent use of capecitabine or by concurrent use
of capecitabine plus Herceptin.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
9
MBC (study JP16003) no evidence of a PK effect of concurrent administration of docetaxel on the
pharmacokinetics of trastuzumab was found.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Data from study JP16003, a single-arm study of Herceptin (4 mg/kg IV loading dose and 2 mg/kg IV
weekly) and docetaxel (60 mg/m2 IV) in Japanese women with HER2- positive MBC, suggested that
concomitant administration of Herceptin had no effect on the single dose pharmacokinetics of
docetaxel. Study JP19959 was a substudy of BO18255 (ToGA) performed in male and female
Japanese patients with advanced gastric cancer to study the pharmacokinetics of capecitabine and
cisplatin when used with or without Herceptin. The results of this substudy suggested that the
exposure to the bioactive metabolites (e.g. 5-FU) of capecitabine was not affected by concurrent use of
cisplatin or by concurrent use of cisplatin plus Herceptin. However, capecitabine itself showed higher
concentrations and a longer half-life when combined with Herceptin. The data also suggested that the
pharmacokinetics of cisplatin were not affected by concurrent use of capecitabine or by concurrent use
of capecitabine plus Herceptin.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
By comparison of simulated serum trastuzumab concentrations after Herceptin monotherapy (4 mg/kg
loading/2 mg/kg q1w IV) and observed serum concentrations in Japanese women with HER2- positive
MBC (study JP16003) no evidence of a PK effect of concurrent administration of docetaxel on the
pharmacokinetics of trastuzumab was found.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Version 2025-11-25T17:43:00Z · SHA-256 4737cd7c26cd2805fc40be61983542b3a3127abbce7e3ca6ebc3b5c0895dda53 · Passage 261c7cfaaeeb233fa49f20e650b34cbf25f451a0aa5ff9decdfe4a401a105160 · Zeichen 2131–2462 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.